Your session is about to expire
← Back to Search
Monoclonal Antibodies
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Phase 2
Waitlist Available
Research Sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to ~30 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called zilovertamab vedotin for patients with different types of cancers that have not improved with other treatments. The drug works by finding cancer cells and destroying them.
Eligible Conditions
- Adenocarcinoma
- Breast cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
- Stomach Cancer
- Ovarian Cancer
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to ~30 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to ~30 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)
Secondary study objectives
AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1
AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1
AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1
+23 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Zilovertamab VedotinExperimental Treatment1 Intervention
Participants will receive intravenous (IV) zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W) or 1.75 mg/kg on Day 1 and Day 8 of each 21-day cycle (Q2/3W). Treatment will continue until progressive disease or discontinuation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zilovertamab vedotin
2019
Completed Phase 1
~100
Find a Location
Who is running the clinical trial?
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Lead Sponsor
1 Previous Clinical Trials
91 Total Patients Enrolled
VelosBio Inc.Lead Sponsor
1 Previous Clinical Trials
91 Total Patients Enrolled
Langdon L Miller, MDStudy DirectorVelosBio Inc.
1 Previous Clinical Trials
91 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,900 Previous Clinical Trials
8,090,332 Total Patients Enrolled
9 Trials studying Breast Cancer
6,044 Patients Enrolled for Breast Cancer